Transcriptional analysis of the mammalian heart with special reference to its endocrine function

Monica Forero McGrath1 and Adolfo J de Bold*1,2

Address: 1Department of Cellular Molecular Medicine, Faculty of Medicine, Cardiovascular Endocrinology Laboratory, University of Ottawa Heart Institute, Ottawa, Canada and 2Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada

Email: Monica Forero McGrath - mforero@ottawaheart.ca; Adolfo J de Bold* - adebold@ottawaheart.ca

* Corresponding author

Abstract

Background: Pharmacological and gene ablation studies have demonstrated the crucial role of the endocrine function of the heart as mediated by the polypeptide hormones ANF and BNP in the maintenance of cardiovascular homeostasis. The importance of these studies lies on the fact that hypertension and chronic congestive heart failure are clinical entities that may be regarded as states of relative deficiency of ANF and BNP. These hormones are produced by the atrial muscle cells (cardiocytes), which display a dual secretory/muscle phenotype. In contrast, ventricular cardiocytes display mainly a muscle phenotype. Comparatively little information is available regarding the genetic background for this important phenotypic difference with particular reference to the endocrine function of the heart. We postulated that comparison of gene expression profiles between atrial and ventricular muscles would help identify gene transcripts that underlie the phenotypic differences associated with the endocrine function of the heart.

Results: Comparison of gene expression profiles in the rat heart revealed a total of 1415 differentially expressed genes between the atria and ventricles based on a 1.8 fold cut-off. The identification of numerous chamber specific transcripts, such as ANF for the atria and Irx4 for the ventricles among several others, support the soundness of the GeneChip data and demonstrates that the differences in gene expression profiles observed between the atrial and ventricular tissues were not spurious in nature. Pathway analysis revealed unique expression profiles in the atria for G protein signaling that included Gα11, Gγ2 and Gγ3, AGS1, RGS2, and RGS6 and the related K+ channels GIRK1 and GIRK4. Transcripts involved in vesicle trafficking, hormone secretion as well as mechanosensors (e.g. the potassium channel TREK-1) were identified in relationship to the synthesis, storage and secretion of hormones.

Conclusion: The data developed in this investigation describes for the first time data on gene expression particularly centred on the secretory function of the heart. This provides for a rational approach in the investigation of determinants of the endocrine of the heart in health and disease.

Background

In all mammals, atrial cardiac muscle cells (cardiocytes) display phenotypic differences with their ventricular counterparts owing to the endocrine function of the former. Atrial cardiocytes contain secretory-like granules known as specific atrial granules, which co-store two
polypeptide hormones, atrial natriuretic factor (ANF or ANP, Nppa) and B-type natriuretic peptide (BNP, Nppb), referred to as cardiac natriuretic peptides (NP).

The increase in atrial NP gene expression and secretion observed during hemodynamic overload is viewed as a cardioprotective mechanism based on the capacity of ANF and BNP to reduce load by modulating renal function, vessel tone, as well as the renin-angiotensin-aldosterone and the sympathetic nervous systems, among others.

Considerable effort has been focused on the elucidation of the mechanistic underlying of ANF and BNP gene expression and secretion by the atrial cardiocytes. The majority of these investigations have concentrated on pharmacological interventions but much remains to be determined regarding specific genes involved in cardiocyte secretory function. This information is important however, to understand why under chronic conditions of hemodynamic overload such as in chronic congestive heart failure, the secretion of ANF and BNP is insufficient as demonstrated by the fact that patients that receive exogenous hormone benefit from the unloading of the heart induced by therapeutic administration of either of the hormones [1]. Through the present work we have defined genes that may be fitted within a more detailed view of cardiac endocrine function.

Results
Differentially expressed genes between atrial and ventricular tissues
From the 31042 probe sets found on the microarray, an average of 59% and 56% of probes had present calls in the atria and ventricles, respectively. Based on a 1.8 fold change ratio criterion, 1415 probe sets were statistically differentially expressed between the atria and ventricles. Of these, 859 probe sets showed higher expression levels in the atrial samples and 556 probe sets showed higher expression levels in the ventricles. The degree of change of the differentially expressed probes ranged between the 1.8 fold minimum set cut-off and 245 fold (see Additional file 1). Chamber specific genes were found differentially expressed in our dataset. Sarcolipin, an atrial-specific Ca^2+ binding protein was expressed 245.97 fold higher in the atria than the ventricles. Other atrial specific genes include dickkopf homolog 3 (DKK3) (3.32 fold), ANF (12.88 fold), and myosin light chain 2a (26.19 fold). In the ventricles, four-and-a-half LIM domain 2 (8.63 fold), myosin light chain polypeptide 3 (14.78 fold) and Iroquois homeobox protein 4 (Irx4) (18.44 fold) were identified. Differential expression of 14 candidate genes was confirmed by real time-PCR. The results show excellent agreement between the microarray and PCR data (Figure 1). Several genes exhibited a higher fold change ratio when analyzed by PCR as compared to microarray.

Functional classification
Differentially expressed genes between the atria and the ventricles were functionally classified into four major Gene Ontology categories: biological process, cellular component, molecular function and unclassified. An individual transcript was included in several categories or subcategories because of its relevance to more than one category or subcategory. Out of the 1415 significantly differentially expressed probes, 837 were grouped as unclassified, i.e. had unknown annotations at the time of the study. Figure 2 illustrates the extent in gene expression differences found between the two heart tissues across functional classes.

Biological processes
Differentially expressed genes were similarly abundant in cell communication and signal transduction processes and they were mainly found involved in cell growth, metabolism, transport, G protein-dependent signaling, and protein kinase cascade (Figure 2). Differentially expressed G protein-dependent signaling transcripts include those grouped in subcategories such as glutamate signaling, G protein signaling, neuropeptide signaling pathway, and serotonin receptor signaling (Table 1). Regulators of G-protein signaling (RGS) RGS2 and RGS6 were more abundant in the atria (2.61 and 2.47 fold, respectively) while RGS5 was prevalent in the ventricles (2.33 fold) (see Figure 3). Other accessory proteins for G proteins that were found differentially expressed include periplakin (4.23 fold), Rasd1 (also known as Activator of G protein Signaling 1, AGS1) (3.75 fold) and β-site APP cleaving enzyme 2 (3.54 fold). These genes were more abundant in the atria while Rasd2 (3.32 fold) and AGS3-like (11.43) were more abundant in the ventricles. All these accessory proteins, including the RGS proteins interact with Ga_i/o [2]. Small GTPase-mediated signal transduction transcripts found differentially expressed include regulators of membrane trafficking including Rab15 (24.53 fold), Rab34 (1.90 fold) and Rab40b (3.27 fold). The Rab escort protein choroideremia, known to interact with Rab3a and Rab27a, as well as the Rab27a effector protein synaptoagmin-like 2 were abundantly expressed in the atria by 1.86 and 32.25 fold, respectively. The latter is known to bind and regulate the GTP-bound form of Ras-related protein Rab27a, which has been shown to positively regulate the exocytosis of secretory granules in pancreatic beta cells and pituitary tissue [3].

Genes involved in secretion included signal sequence receptor gamma (SSR3) (1.82 fold), blocked early in transport 1 homolog (S. cerevisiae) (Bet1) (1.93 fold), vesicle trafficking protein like 1 (Sec22) (1.93 fold), synapsin III (1.93 fold) and annexin A1 (2.04 fold). These genes were found more abundant in the atria when compared to the ventricles.
**Cellular component**

Within the Gene Ontology category of cellular components, the intracellular components subcategory contained the largest amount of differentially expressed genes (n = 156) in comparison to the extracellular (n = 37) and the membrane components (n = 37). Cellular components that had prominent atrial abundant transcripts included those associated with the plasma membrane, the endoplasmic reticulum (ER), the Golgi apparatus, and the nucleus, while the ventricles were associated with abundant transcripts found within the mitochondrion and peroxisome components (Figure 2). ER and Golgi-associated genes that were abundantly expressed in the atria include stearoyl-CoA desaturase 1 (20.81 fold) and 2 (2.21 fold), inositol 1,4,5-triphosphate receptor 1 (2.44 fold), ribosome associated membrane protein 4 (2.22 fold), Sec11 like 3 (2.05 fold), as well as SSR3. Transcripts involved in ER to Golgi vesicle-mediated transport include the previously mentioned genes Sec22 and Bet1. Other atrial abundant Golgi resident proteins include islet cell autoantigen of 1 (Ica1) (4.63 fold), transforming growth factor-β2 (TGFβ2) (3.89 fold), nucleobindin 2 (2.35 fold) and Golgi transport 1 homolog B (Golg1b) (2.60 fold).

**Molecular function**

The molecular function subcategories that were most notably differentially expressed between atrial and ventricular muscles included enzyme, signal transducer, structural protein, and transport (see Figure 2). The signal transducer subcategory is composed of ligands and receptors (see Additional file 2 and Additional file 3 for complete list of genes). The cytokines, frizzled receptor ligands, growth factor receptor ligands as well as hormone receptor ligands subcategories were also significantly differentiated. Differentially expressed genes involved in hormone, hormonal activity, and hormone receptor ligand subcategories were also significantly differentiated. Differentially expressed genes involved in hormone, hormonal activity, and hormone receptor ligand subcategories, including ANF (12.88 fold) and BNP (1.89 fold), as well as secretory granule neuroendocrine

---

**Figure 1**

Comparison of microarray and real-time PCR results. Relative fold change of 14 candidate genes are shown. The results demonstrate agreement between the microarray and RT-PCR data, although the degree of fold change can vary.
protein 1 (SGNE1) (3.20 fold) are listed in Table 2. Preliminary immunohistochemistry analysis localized SGNE1 in structures compatible with adrenergic varicosities (Figure 4). Differentially expressed transcription factors/DNA binding proteins were more abundant in the atria than in the ventricles (see Additional file 4 for complete list).

In general, genes coding for transport proteins were more abundant in the atria than in the ventricles. Potassium channels, which were most abundant in the atria included potassium channel subfamily K member 2 (Kcnk2 or TREK-1), as well as potassium inwardly-rectifying channel, subfamily J, member 3 (Kcnj3) and 5 (Kcnj5) (Table 3). The ventricles were most abundant in the potassium inwardly-rectifying channel, subfamily J, member 8 (Kcnj8 also known as Kir6.1) channel subunit.

Pathway analysis
Pathway analysis using the Gene Map Annotator and Pathway Profiler (GenMapp) software identified clusters of differentially expressed genes found within the same biological pathway. Visual representation of specific known pathways, referred as Mapps, revealed several Mapps in which atrial gene expression was predominant. These Mapps included pathways of fatty acid synthesis, prostaglandin synthesis, as well as eicosanoid synthesis, which shows a higher abundance of phospholipase A2 (PLA2) (3.28 fold), COX1 (2.11 fold) and COX2 (1.96 fold). In contrast, mitochondrial long-chain fatty acid β-oxidation and glucocorticoid metabolism pathways were dominant in ventricular samples. Mapps other than those from metabolic processes, revealed atrial regional specialization in regards to the classical component activation pathway and G-protein signaling pathway (Figure 5).
Figure 3
Normalized intensity values of specific transcripts in all atrial and ventricular microarray replicates. The data is displayed in four different panels for visual simplicity. Note that atrial and ventricular microarrays are labelled as LA(n) and LV(n), and the scale of the ordinate axis is different for the upper panel due to high signal intensity values for ANF and BNP. Also note that RGS5 and Kcnj3 are represented by two distinct probe sets.
Table 1: List of differentially expressed genes classified into G protein dependent signaling and related functional groups

| Functional Group/Probe set ID | Gene Description                                      | Fold change |
|-------------------------------|--------------------------------------------------------|-------------|
| **G Protein signaling**       |                                                        |             |
| 1369740_at                   | Potassium inwardly-rectifying channel, subfamily J, member 3 | 7.76        |
| 1368560_at                   | Potassium inwardly-rectifying channel, subfamily J, member 5 | 7.68        |
| 1369741_at                   | Potassium inwardly-rectifying channel, subfamily J, member 3 | 6.35        |
| 1369273_a_at                 | Natriuretic peptide receptor 3                         | 6.02        |
| 1396249_at                   | Natriuretic peptide receptor 3                         | 4.06        |
| 1387803_at                   | Protein phosphatase 2, regulatory subunit B, beta isoform | 3.94        |
| 1367920_at                   | Endothelial differentiation, sphingolipid G-protein-coupled receptor, 5 | 3.27        |
| 1367791_at                   | Receptor (calcitonin) activity modifying protein 1      | 3.05        |
| 1392905_at                   | Guanine nucleotide binding protein, gamma 2            | 2.74        |
| 1368879_a_at                 | Guanine nucleotide binding protein, alpha o            | 2.31        |
| 1369377_at                   | Hypocretin receptor 2                                  | 2.00        |
| 1373202_at                   | Guanine nucleotide binding protein, gamma 3            | 1.96        |
| 1369647_at                   | Calcitonin receptor-like                               | -1.82       |
| 1369115_at                   | Adrenergic receptor, beta 2                            | -1.83       |
| 1368660_at                   | cAMP-regulated guanine nucleotide exchange factor I    | -1.93       |
| 1388109_at                   | G protein-coupled hepta-helic receptor Ig-Hepta         | -1.95       |
| 1370449_at                   | G protein-coupled receptor 105                         | -2.20       |
| 1368534_at                   | Adrenergic receptor, alpha 1d                          | -2.34       |
| 1398530_at                   | guanine nucleotide binding protein (G protein), gamma 11 | -2.34       |
| 1368300_at                   | Adenosine A2a receptor                                 | -2.46       |
| 1370522_at                   | Glucagon receptor                                      | -3.07       |
| 1395473_at                   | Guanine nucleotide binding protein, beta 3             | -3.65       |
| 1387671_at                   | Secretin receptor                                      | -4.31       |
| **Accessory proteins for G proteins** |                                                        |             |
| 1391187_at                   | Periplakin (predicted)                                 | 4.23        |
| 1387908_at                   | RAS, dexamethasone-induced 1 (Rasd1/AGS1)              | 3.75        |
| 1377390_at                   | Beta-site APP-cleaving enzyme 2                        | 3.54        |
| 1387074_at                   | Regulator of G-protein signaling 2                     | 2.61        |
| 1379517_at                   | Regulator of G-protein signaling 6                     | 2.47        |
| 1369957_at                   | Regulator of G-protein signaling 5                     | -2.33       |
| 1370372_at                   | RASD family, member 2                                  | -3.32       |
| 1372383_at                   | G-protein signaling modulator 1 (AGS3-like, C. elegans) | -11.43      |
| **Neuropeptide signaling pathway** |                                                        |             |
| 1367992_at                   | Secretory granule neuroendocrine protein 1             | 3.20        |
| 1382967_at                   | G protein-coupled receptor 64                          | 2.50        |
| 1369377_at                   | Hypocretin receptor 2                                  | 2.00        |
| 1368428_at                   | X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound | -1.99       |
| 1371696_at                   | G protein-coupled receptor 56                          | -2.16       |
| 1367949_at                   | Preproenkephalin                                       | -13.55      |
| **Serotonin receptor signaling** |                                                        |             |
| 1369125_at                   | 5-hydroxytryptamine (serotonin) receptor 2A             | 7.84        |
| 1369124_at                   | 5-hydroxytryptamine (serotonin) receptor 2A             | 1.88        |

Positive fold change values indicate a higher abundance in the atria as compared to the ventricles, while negative fold change values demonstrate a higher ventricular abundance in comparison to the atria.
latter demonstrated a higher abundance of the $G_{\alpha_1}$ subunit ($Gnao$), $Kcnj3$ and $Kcnj5$ in the atrium compared to the ventricle by 2.3, 6.35 (second probe set = 7.76 fold) and 7.68 fold, respectively. Also, $G_{\gamma_2}$ ($Gng2$), $G_{\gamma_3}$ ($Gng3$) (2.74 and 1.96 fold, respectively) and phosphodiesterase 7a (Pde7a) (7.52 fold) as well as inositol 1,4,5-triphosphate receptor 1 (Itpr1) (2.44 fold) were highly expressed in the atria while protein kinase C epsilon ($Prkce$) was more abundant in the ventricles by 2.09 fold. $G\beta$ subunits 1, 2, and 5 were present in both atria and ventricles at roughly similar levels while $G\beta_3$ ($Gnb3$) was expressed at higher levels in the ventricles (3.66 fold).

**Discussion**

Mammalian atrial and ventricular cardiocytes display striking differences in phenotype. The bulk of atrial cardiocytes have, in addition to features commonly associated with striated cardiac muscle cell cytology, organelles that are normally found in cells engaged in the synthesis, vesicular transport and secretion of polypeptide hormones. These include an abundance of rough endoplasmic reticulum, a highly developed Golgi complex and storage granules containing hormonal products. These cytological features led to a series of past investigations that culminated in the discovery of the endocrine function of the heart [4], which is largely mediated by the polypeptide hormones ANF and BNP.

From the data presented here it is evident that the phenotypic differences between the atria and the ventricles results from underlying differences in degree or presence/absence of several specific genes. Despite this complex background of differential expression, the microarray data reproducibility observed in different biological replicates was excellent.

The proportion of probes that were called present, as well as the number of differentially expressed genes was higher in the atria than in the ventricles. This observation could be related to a higher functional complexity of the atrial tissue, which include contraction, excitation, conduction, secretion and the presence of a diffuse innervation [5,6]. The detection of numerous known chamber specific transcripts [6-9] supports the robustness of the GeneChip data and demonstrates that the differences in gene expression profiles observed between the atrial and ventricular tissues are not spurious in nature. A comparative analysis of the differentially expressed genes identified in other studies that are in common with our data is presented in the Additional file 5. Several genes identified in these studies by others are in agreement with our data, even though there are experimental differences (such as species, gender and tissue selection) as well as data analysis between studies. However, none of these previous studies focused specifically on gene expression profiles relating to the endocrine function of the heart.

Based on atrial and ventricular phenotypical differences, the strategy used in the data mining process was to identify genes that had Gene Ontology annotations relating to hormone secretion, hormone activity, vesicle/granule packaging and transport. Screening for Gene Ontology terms classified as Golgi apparatus and ER cellular components was also undertaken in an effort to identify genes involved in the regulation of NP packaging and secretion. Differentially expressed transcription factors as well as transcripts coding for proteins involved in signal transduction such as ligands and receptors were also of great interest. Finally, hormone secretion can be modulated/regulated by ion channels and mechanosensors, hence genes coding for transport proteins were also of interest. Differentially expressed genes coding for proteins involved in metabolic processes as well as contractile proteins were not specifically looked at since these differences are expected to be found between the atrial and ventricular tissues but are not thought to be involved in the endocrine function of the heart. In general, functional classification of the differentially expressed genes according to their cellular components, identified in our study, parallels the results obtained by Barth et al.,[5], which include ventricular abundance of mitochondrial genes as well as the identification of numerous atrial abundant ER and Golgi apparatus transcripts, such as Sec22 and Rab34. The larger number of probes hybridizing to cellular components involved in secretory function agrees with the...
phenotypic and functional differences between atrial and ventricular muscle. For example, atrial cardiocytes were more abundant in the transcripts coding for ANF and BNP than the ventricles. Correspondingly, ANF transcript abundance, which constitutes one to three percent of total atrial mRNA [10] was found to provide for the top one percent of the GeneChip® signal intensities. Saturation of the fluorescent signal is thought to have occurred for ANF probe sets, which explains the plateau level of 12 fold difference between atrial vs. ventricular tissues as compared to 163 fold with RT-PCR (Figure 1). Oligonucleotide probe saturation can occur when the labeled cRNA is at high enough levels to result in an almost 100% probe/cRNA hybridization complex. Any other increase in expression would not be measurable due to the oligonucleotide hybridization saturation. It is difficult to estimate the amount of cRNA needed to saturate the oligonucleotide probes tiled onto the $11^2$ micron surface area of the GeneChip® is proprietary information.

Storage granule-associated proteins identified in this study include Ica1 [11] and SGNE1. The evolutionary conserved gene Ica1, was shown to be abundant in human pancreas and heart, and moderately expressed in brain [12]. Variable expression of 5'-untranslated region exons from the Ica1 gene was shown to be tissue specific, where cardiac tissue distinctively expressed the exon B2 transcript variant [13]. The original observation that Ica1 expression levels were high in the heart but null in skeletal muscle lead Pietropaolo et al., [12] to postulate that Ica1 was present in selective cells. We demonstrate here that Ica1 is expressed specifically in the atria given that all four ventricular replicates exhibited an absent detection call for this transcript (an absent call indicates that the microarray

Table 2: List of differentially expressed genes possessing hormone, hormonal activity, or hormone receptor ligand Gene Ontology annotations

| Probe Set ID  | Gene Description                                           | Fold change |
|--------------|------------------------------------------------------------|-------------|
| 1367564_at   | Natriuretic peptide precursor type A (ANF)                 | 12.88       |
| 1367616_at   | Natriuretic peptide precursor type B (BNP)                 | 1.89        |
| 1371400_at   | Thyroid hormone responsive protein                         | 38.59       |
| 1387396_at   | Hepcidin antimicrobial peptide                             | 11.24       |
| 1369484_at   | WNT1 inducible signaling pathway protein 2                  | 4.79        |
| 1387625_at   | Insulin-like growth factor binding protein 6                | 3.61        |
| 1368883_at   | Top of Form Nephroblastoma overexpressed gene Bottom of Form | 3.51        |
| 1367992_at   | Secretory granule neuroendocrine protein 1 (SGNE1)         | 3.20        |
| 1368367_at   | CUB and zona pellucida-like domains 1                       | 3.17        |
| 1368367_at   | Integral membrane-associated protein 1                      | 3.16        |
| 1376734_at   | Nephroblastoma overexpressed gene                           | 2.79        |
| 1372168_s_at | Insulin-like growth factor binding protein 6                 | 2.25        |
| 1367631_at   | Connective tissue growth factor                             | 2.20        |
| 1389651_at   | Apelin, AGTR1 ligand                                        | 2.00        |
| 1387219_at   | Adrenomedullin                                              | 1.87        |
| 1367894_at   | Growth response protein (CL-6)                              | 1.82        |
| 1370563_at   | 3-alpha-hydroxysteroid dehydrogenase                        | -1.92       |
| 1368428_at   | X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound | -1.99       |
| 1396101_at   | Stanniocalcin I                                             | -2.14       |
| 1368468_at   | Cytochrome P450, subfamily 11A                              | -3.97       |
| 1367949_at   | Preproenkephalin, related sequence                          | -13.55      |

Positive fold change values indicate a higher abundance in the atria as compared to the ventricles, while negative values demonstrate a higher ventricular abundance in comparison to the atria.

Table 3: List of differentially expressed genes encoding for potassium channels

| Probe Set ID  | Gene Description                                           | Symbols      | Fold Change |
|--------------|------------------------------------------------------------|--------------|-------------|
| 1369740_at   | Potassium inwardly-rectifying channel, subfamily J, member 3 | Kcnj3 or GIRK1 | 7.78        |
| 1368560_at   | Potassium inwardly-rectifying channel, subfamily J, member 5 | Kcnj5 or GIRK4 | 7.67        |
| 1369741_at   | Potassium inwardly-rectifying channel, subfamily J, member 3 | Kcnj3 or GIRK1 | 6.36        |
| 1370342_at   | Potassium channel, subfamily K, member 2                    | Kcnk2 or TREK-1 | 4.17        |
| 1368911_at   | Potassium inwardly-rectifying channel, subfamily J, member 8 | Kcnj8 or Kir6.1 | -2.03       |

Positive fold change values indicate a higher abundance in the atria as compared to the ventricles, while negative values demonstrate a higher ventricular abundance in comparison to the atria.
expression level for a particular transcript was below the threshold of detection).

Several studies have been able to co-localize SGNE1, a member of the secretogranin family, with neuropeptides and hormones in various tissues that are primarily composed of neuronal or endocrine cells, as well as tissues known to contain a sub-population of neuroendocrine cells [14]. RT-PCR analysis further confirmed atrial abundance of SGNE1 (Figure 1). SGNE1 has not been previously associated with the atria or the heart. Our own immunofluorescence preliminary data suggest that SGNE1 protein is localized in structures compatible with adrenergic varicosities (Figure 4).

Differentially expressed transcription factors/DNA binding proteins that were more abundant in the atria than in the ventricles included numerous orphan nuclear receptors. Two out of the three Affymetrix probe sets assaying for nuclear receptor subfamily 2, group F, member 2 (Nr2f2) transcripts were identified in the atrial abundant gene list. Nr2f2 expression pattern is in agreement with previously published data (Additional file 5) and real-time PCR analysis further validated its atrial abundance (Figure 1). Other atrial abundant transcription factors include paired-like homeodomain transcription factor 2 (Pitx2), which is involved in atrial septation; T-box protein 5 (Tbx5), a known activator of the ANF promoter; and early growth response 1 (Egr1), which is up-regulated during endothelin, angiotensin II, ischemia and stretch treatments. Hairy/enhancer-of-split related with YRPW motif 1 (Hey1), as well as its activator Notch1, were more abundant in the ventricles than in the atria. Hey1 is thought to repress ANF expression in the ventricles [15].

**Figure 5**

**G protein signaling pathways generated by GenMapp.** Genes labeled in red indicate a higher expression level in the atria as compared to the ventricles based on a 1.8 fold threshold cut-off. Genes labeled in blue indicate a higher expression level in the ventricles as compared to the atria based on a -1.8 fold threshold cut-off. Genes labeled in white were not found in the list of statistically significant differentially expressed genes that was uploaded in GenMapp.
The known tissue specificity of several of these transcription factors further illustrates the soundness of the dataset and the identification of novel atrial abundant DNA binding proteins warrants further attention.

Of special importance to the understanding of the regulation of hormone secretion by the atria are genes that encode for molecular species involved in mechanical aspect of atrial activity given that a major stimulus for ANF and BNP secretion is atrial muscle stretch. This phenomenon is referred to as "stretch-secretion coupling" [16]. Questions still remain regarding the exact stimulus perceived by the atrial cardiomyocytes as well as the precise signal transduction cascade that leads to an increase in ANF and BNP secretion following stretch. Therefore, the finding that mechanoreceptors (mechanically gated ion channels) as well as mechanosensors (PLA2) are most abundant in the atria is central to the generation and the testing of hypothesis. Because some prostaglandins are known to be potent stimulators of ANF synthesis and secretion [17], it is of interest that the mechanosensor PLA2 is abundantly expressed in the atria. Activation of PLA2 following plasma membrane stretch could cause the release of arachidonic acid, a substrate for prostaglandin synthase.

The rapid secretory response following stretch of atrial cardiocytes as compared to the response to other ANF secretion agonists such as endothelin-1 (ET-1) [18] has long suggested that the phenomenon of stretch-secretion coupling is related to mechanosensitive ion channels. It has been suggested [19-22] that K_ATP channels are involved in stretch-secretion coupling. These channels are stretch-sensitive [23], are known to couple to G proteins, including Gαi/0, 24,25, and have been associated with other secretory processes [26-28]. The results and conclusions reached from investigations on the involvement of K_ATP channels on ANF secretion have often been contradictory. An inspection of the literature suggests that a likely reason for these discrepancies may lie on differences in experimental systems (in vivo or in vitro, perfused or non perfused tissues, etc.) [19-22]. Most importantly, pharmacological studies have been made with little reference to the several candidate ion channels that may be present in the atria. The present investigation shows that Kir6.1 is significantly expressed in the ventricles. The ATP binding cassette SUR2, whose expression level (1.79 fold) didn’t meet the fold cut-off criteria was more abundant in the ventricles, and, while not significant, Kir6.2 and SUR1 had marginally higher expression in a atria.

Three other channels had significantly higher levels of expression in the atria over the ventricles. These included the inward rectifiers Kcnj3, Kcnj5 and the background channel TRENK-1. Kcnj3,5 channels, which are activated by G protein coupled receptors (GPCRs) coupled to pertussis toxin (PTX) sensitive Gβγ proteins, exhibit mechanosensitive properties and might participate in a mechanoelectrical feedback pathway regulating ANF and BNP secretion [29,30]. This view is in line with our recent finding that PTX can abolish stretch secretion coupling [31]. The background channel TRENK-1 produces an outwardly rectifying current and is a member of the 2 pore domain potassium (K2P) channel family. TRENK-1 has been characterized as a stretch-activated membrane channel. It is primarily expressed in the central nervous system but has been found in cardiac tissues [32] as well as in specific endocrine cells, such as adrenocortical cells [33]. Atrial abundance of TRENK-1 was further validated by RT-PCR (Figure 1). Immunohistochemical analysis localized TRENK-1 protein in isolated adult rat atrial cardiocytes and it is suggested that TRENK-1 may act as a regulator of ANF secretion [34].

The complex signal transduction pathways resulting from the activation of GPCRs is in part orchestrated by an assorted population of G proteins, assembled from various combinations of 20 Ga, 5 Gβ and 12 Gγ isoforms [2]. Pathway analysis of the microarray data revealed differential expression of genes involved in G protein signaling pathways between atrial and ventricular tissues. The G protein Ga_i, isoform 1 was found more abundant in the atria by both microarray and RT-PCR analyses and was demonstrated by immunohistochemistry to co-localize with ANF in atrial granules and in the sarcolemma [31]. Differential expression of the Gβ and Gγ subunit isoforms was also observed between the atria and ventricles but the functional significance of the differential G protein subunit diversity is not well known.

The identification of accessory proteins involved in the modulation of G protein signal transduction has helped to gain insight into the mechanisms involved in the specificity of a cellular response from an assortment of external stimuli. RGS proteins are capable of inhibiting signaling by acting as a GTPase Accelerating/Activating Protein (GAP), which accelerate the intrinsic rate of GTP hydrolysis of the Gαi/o subunit [35]. The preponderance of genes encoding for RGS proteins appears to be tissue specific. RGS2 and RGS6 were abundantly expressed in the atria while RGS5 was found at higher levels in the ventricles. These findings are confirmed by other studies in which RGS mRNA and protein levels were measured within atrial and ventricular cardiocytes [35-37].

In addition to the previously mentioned accessory proteins, in this work we identified the atrial specific transcript Rasd1, also known as AGS1. AGS1 was found more abundant in the atria by both microarray and RT-PCR analyses. In the absence of receptor stimulation, AGS1, a member of the Ras subgroup of small G proteins, specifi-
cally activates $G_{i/o}$ heterotrimeric signaling pathways by promoting nucleotide exchange on $G_{i/o}$ proteins and enhancing $G_{i/o}$ uncoupling of $G_{i/o}$ [38]. Since stretch secretion coupling of ANF and BNP is mediated by PTX-sensitive $G_{i/o}$, the differential expression of AGS1, as well as the other accessory proteins for $G$ proteins identified in this investigation, is of particular interest. Due to AGS1 opposing effects on $G_{i/o}$ mediated signaling following agonist dependent or independent GPCR activation [39-42], AGS1 may help orchestrate the complex diversity and specificity of $G$ protein signaling under different conditions.

**Conclusion**

The data developed in this investigation describes for the first time data on gene expression particularly centred on the secretory function of the heart. Based on our data mining strategy, we narrowed down the list of the 1415 differentially expressed genes to a group of 115 genes. Additional data filtering generated a subset of 20 candidate genes, described herein, that are likely involved in the endocrine function of the heart. Of special interest is the relationship between $G$ proteins of the inhibitory type, as well as their accessory proteins, and members of the inward rectifiers and the two pore domain K channel superfamily. This investigation provides the basis of hypotheses formulation to further explore the endocrine function of the heart in physiological and pathophysiological conditions. Several lines of investigation are being pursued in our laboratory based on the findings described herein.

**Methods**

**Total RNA extraction**

The left atria appendage and the left ventricular free wall were obtained from thirteen normal male Sprague Dawley rats (225–275 g; Charles River Laboratories, Wilmington, MA), sacrificed by decapitation. The experimental protocol was carried out according to the Canadian Council on Animal Care Guide to the Care and use of Experimental Animals following approval by the University of Ottawa Animal Care Committee. The tissues were snap-frozen in liquid nitrogen and stored at -80°C. Atrial and ventricular tissues were grouped and then divided into 4 pools from which total RNA was extracted using Trizol® (Invitrogen, Carlsbad, CA) following the manufacturer’s instructions.

**Microarray hybridization**

The quality of the extracted RNA from four independent pools of atrial and ventricular tissue was assessed using an Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA). Ten μg of total RNA was used to generate the first strand cDNA using the one cycle target labeling protocol. The biotin-labeled cRNA was prepared according to the manufacturer’s protocol and hybridized to the GeneChip® Rat Genome 230 2.0 Array (Affymetrix, Santa Clara, CA) which contains 31042 probe sets and analyses over 30000 transcripts from 28000 genes. Detailed description of the hybridization protocol is available at:

https://genomequebec.mcgill.ca/nanuqAdministration/nanuq-administration/protocols.go

Four biological replicates for each muscle type were generated. These steps were carried out by the Genome Québec Innovation Centre (Montreal, QC).

**Data analysis**

The files that contain cell intensities (.CEL) were visually inspected with the dChip http://www.dchip.org software as a quality control measure in order to identify local image contamination prior to normalization. Preliminary expression summaries produced by Microarray Suite 5.0 (Affymetrix, Santa Clara, CA) (MASS) software were used to generate scatterplots, to assess microarray reproducibility, and detection calls. The normalized signal intensities from the normal atrial replicates as well as from the normal ventricular replicates were visualized by pairwise scatterplots in which individual chips within the same group were plotted against each other (within-class). The majority of data points representing signal intensities for both atrial and ventricular tissues were highly correlated for the four replicates.

Further analysis was conducted using the expression level summary files computed by Robust Multiple-Array Averaging (RMA) which is implemented in Bioconductor http://www.bioconductor.org. We used the RMA summary method, which generates background adjustments, quantile normalizations and summarizations of the raw scanned data in order to produce a measure of mRNA expression levels. It has been shown that RMA has superior precision, better estimation of fold change and provides higher specificity and sensitivity when analyzing fold changes to detect differentially expressed genes [43,44]. Differential expression of genes was considered to be significant based Significance Analysis of Microarrays (SAM) http://www-stat.stanford.edu/~tibs/SAM with a False Discovery Rate (FDR) of 0.01%. Genes were considered biologically differentially expressed based on an up- or down-regulation of expression levels by at least 1.8 fold (log base 2 = 0.848). The complete filtered raw data can be found in Additional file 1. Sample hierarchical clustering was performed with TIGR MeV software http://www.tigr.org/software/tm4/index.html using the Pearson uncentered correlation with complete linkage. Pathway analysis, which identifies biologically relevant networks that exist among differentially expressed genes, was done by GenMAPP software http://www.genmapp.org Functional classification was carried out using GeneSpring 7.0 http://www.silicongenetics.com and NetAffx http://www.genome.ucsc.edu/pani/
www.affymetrix.com software. The microarray data has been deposited in the National Center for Biotechnology Information’s Gene Expression Omnibus (GEO) and complies with MIAME standards (accession number: GSE5266).

**Real-time PCR**

Real-time PCR was used to validate expression profiles of transcripts using the Roche LightCycler 480 relative quantification software. Standard curves were performed in triplicate for each primer pair. G6PD was used as the reference gene. RT-PCR was performed in quadruplet for each gene and the median crossing point was used to determine the concentration ratio, based on the relative standard curves for each target and reference gene. Most primer nucleotide sequences were obtained from the literature and validated by PRIMER3 http://frodo.wi.mit.edu. Primer sequences are listed in Table 4.

**Immunohistochemistry**

Paraffin-embedded, paraformaldehyde-fixed rat atrial tissue sections were deparaffinized in toluene and hydrated in a graded alcohol series. The sections were incubated for 30 minutes in 3% H2O2/methanol, washed for 5 minutes in PBS, blocked with 5% normal goat serum in PBS for 60 min followed by a single wash in PBS and incubated with the primary antibody in 2% normal goat serum, 2% BSA in PBS overnight at 4°C, and then incubated for 60 min with biotinylated anti-rabbit IgG. The primary antibody dilution of secretogranin V antibody (SGNE1) (ab22699, Abcam, Cambridge, MA) was 1:500. The slides were then washed in PBS, incubated with Fluorescein Avidin D for 30 min, washed in PBS and distilled water and mounted using Vectashield mounting media (Vectorlabs), and examined with a Leica fluorescence confocal microscope.

**Authors’ contributions**

MFM collected the samples, performed the analysis of the microarray data, carried out the real-time RT-PCR experiments, and drafted the manuscript. AJdB participated in the design and coordination of the experiment, assisted in the interpretation, and contributed to the discussion. All authors have read and approved the final manuscript.

**Additional material**

Table 4: Oligonucleotide sequences used for real-time PCR

| Name | Forward Primer | Reverse Primer |
|------|----------------|----------------|
| ANF  | GCCGGTAGAAGATGAGTCA | GGGCTCAATCTGTCAATC |
| AGS1 | GCGGCGAAACTACAGTTG | TGTCTAAGCTGAACCCAGAATGA |
| Bet1 | AAGCAATGGGAGACGCAAA | GAGGAAAGAACGCCCCTAC |
| BNP  | TCGTCTCTCTCTCTTCTTA | GAACTATGCTCCATCTTGG |
| G6PD | CCAGCGCTTCAAGACCTCCTCAA | AATAGCTCCACACCATCAGTA |
| Gxox | GTCACTCAGACATCATCTG | AGTGTACAGGGGCTTGG |
| Kcnj5 | TCCTTCTTCTGCAAGCCATC | TTTTCAAGGTTAGGACTTG |
| Kir6.1 | CACAAAGAACATCCGAGAGCA | CAGACTCCAGGCACTCCTT |
| Nr2f2 | AAAGTCCTCAATAGTCTGGT | ATATCCCGGATGAGGTTT |
| Pitx2 | GTACCAGGCTACTCGTACA | CACCATGCTGGAGCACTAC |
| RGS2 | ATGGAAAGACCGCTTGGAGCTA | TCCCTAGGAGAAGGCTTGAATA |
| RGS6 | ATGGCGGCGTGGTGAAGAATC | AAGGTCTTACGGGCTTGG |
| Sec22 | GCCAGATGTCAGAGGATCA | ATCTCAAGGGCCACCAAAAC |
| SGNE1 | TCCAAATCCTCCCTGCTCTTG | TCCAGGCCTCCTTCCTTG |
| TREK-1 | GTGCCCTCCTGCTGCTCTC | ACGAGGATCCAGAAACACAC |

Additional file 1

Filtered signal intensities data of atrial and ventricular biological replicates. List of 1415 differentially expressed genes. Normalized signal intensities are shown for left atrial replicates (LA (n)) and left ventricular replicates (LV (n)). The average signal intensities of each probe set within the atrial and ventricular groups were calculated and the difference between the two averages was determined (log2 ratio). Click here for file [http://www.biomedcentral.com/content/supplementary/1471-2164-10-254-S1.xls]

Additional file 2

Differentially expressed genes between normal left atrial and left ventricular tissues classified into the Ligand related functional groups. Positive fold change values indicate a higher abundance in the atria compared to the ventricles, whereas negative fold change values demonstrate a higher ventricular abundance in comparison to the atria. Click here for file [http://www.biomedcentral.com/content/supplementary/1471-2164-10-254-S2.xls]
Acknowledgements

This work was supported by grants from the Canadian Institutes of Health Research. We would like to thank Dr. Mercedes L. Kuroski de Bold and Vanja Vukic for their contribution with the immunohistochemistry.

References

1. de Bold AJ, de Bold ML: Determinants of natriuretic peptide production by the heart: basic and clinical implications. J Investig Med 2005, 53:371-377.
2. Sato M, Blumer JB, Simon V, Lanier SM: Accessory proteins for G proteins: partners in signaling. Annu Rev Pharmacol Toxicol 2006, 46:151-187.
3. YI Z, Yokota H, Torii S, Aoki T, Hosaka M, Zhao S, et al: The Rab27a/granuphilin complex regulates the exocytosis of insulin-containing dense-core granules. Mol Cell Bioi 2002, 22:1858-1867.
4. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H: A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 1981, 28:89-94.
5. Barth AS, Merk S, Arnold E, Zwermann L, Kloos P, Gebauer M, et al: Functional profiling of human atrial and ventricular gene expression. Pflugers Arch 2005, 450:201-208.
6. Ellinghaus P, Scheubel RJ, Dobrev D, Ravens U, Holtz J, Hueetter E, et al: Comparing the global mRNA expression profile of human atrial and ventricular myocardium with high-density oligonucleotide arrays. J Thorac Cardiovasc Surg 2005, 129:1383-1390.
7. Small EM, Krieg PA: Molecular regulation of cardiac chamber-specific gene expression. Trends Cardiovasc Med 2004, 14:13-18.
8. Zhao XS, Gallardo TD, Lin L, Schagenman JJ, Sholet RV: Transcriptional mapping and genomic analysis of the cardiac atria and ventricles. Physiol Genomics 2002, 12:53-60.
9. Tabibiazar R, Wagner RA, Liao A, Quertermous T: Transcriptional profiling of the heart reveals chamber-specific gene expression patterns. Circ Res 2003, 93:1193-1201.
10. Seidman CE, Bloch KD, Klein KA, Smith JA, Seidman JG: Nucleotide sequences of the human and mouse atrial natriuretic factor genes. Science 1984, 226(4679):1206-1209.
11. Spitzenerberger F, Pietropolo S, Verkade P, Habermann B, Lucas-Gervais S, Mzaouet H, et al: Iset cell autoantigen of 69 kDa is an arfapton-related protein associated with keratinocytes in the epidermis of insulinoma INS-1 cells. J Biol Chem 2003, 278:2616-26173.
12. Pietropolo M, Castano L, Babu S, Buelow R, Kuroski ML, Martin S, et al: Iset cell autoantigen 69 kDa (ICA69) Molecular cloning and characterization of a novel diabetes-associated autoantigen. J Clin Invest 1993, 92:359-371.
13. Friday RP, Pietropolo SL, Profozich J, Truc Available at http://www.biomedcentral.com/content/supplementary/1471-2164-10-254-S3.xls
14. Zhao XS, Gallardo TD, Lin L, Schageman JJ, Shohet RV: Alternative core promoters regulate tissue-specific expression from the autoimmune diabetes-related ICA1 (ICA69) gene loci. J Biol Chem 2003, 278:853-863.
15. Mlakay M, Seidah NG, Christen M: Neuroregulin secretory protein 78B: structure, expression and functions. Biochem J 2001, 357:329-342.
16. Fischer A, Klaattig J, Knetz B, Diez H, Maier M, Holzmann B, et al: Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 expression and transcription of the GATA target gene ANF in fetal hearts. Mol Cell Biol 2005, 25:8960-8970.
17. Kuroski de Bold ML, de Bold AJ: Stretch-secretion coupling in atrial cardiocytes. Dissociation between atrial natriuretic factor release and mechanical activity. Hypertension 1991, 18:III-169-III-178.
18. Frolod G, Galzignato G, Zanetti M, Montopoli M, Dorigo P, Caparrutta L: Are prostatonoids related to positive inotropism by UTP and ATP? Pharmacology 2003, 73:1-18.
19. Ogawa M, Yata M, Bruneau BG, de Bold AJ: Characterization of natriuretic peptide production by adult heart atra. Am J Physiol Heart Circ Physiol 1999, 276:H1977-H1986.
20. Kim SH, Cho KW, Chang SH, Kim SZ, Chee SW: Gilbenciamide suppresses stretch-activated ANP secretion: involvements of K+ATP channels and L-type Ca2+ channel modulation. Pflugers Archiv-Eur J Physiol 1997, 434:362-372.
21. Jiao PH, Baumann M, Baron A, Roati A, Pences RA, Baertschi AJ: Sulfonylurea receptor ligands modulate stretch-induced ANF secretion in rat atrial myocyte culture. Am J Physiol Heart Circ Physiol 2000 Jun; 278 (6):H2028-38 2000, 278:H2028-H2038.
22. Xu T, Jiao PH, Pences RA, Baertschi AJ: ATP-sensitivity potassium channels regulate stimulated ANF secretion in isolated rat heart. Am J Physiol Heart Circ Physiol 1996, 271:H2339-H2345.
23. Sato N, Sato T, Saito T, Tamagawa M, Kosuro H, Nakaya H: Kir6.2-deficient mice are susceptible to stimulated ANP secretion: K(ATP) channel acts as a negative feedback mechanism? Cardiovasc Res 2005, 67:60-68.
24. Van Wagoner DR: Mechanosensitive gating of atrial ATP-sensitive potassium channels. Circ Res 1993, 73:973-981.
25. Sanchez JA, Gonoi T, Inagaki N, Katada T, Seino S: Modulation of reconstituted ATP-sensitive K(+) channels by GTP-binding proteins in a mammalian cell line. J Physiol 1998, 507(Pt 2):315-324.
26. Zaugg M, Schaub MC: Signaling and cellular mechanisms in cardiac protection by ischemic and pharmacological preconditioning. J Muscle Res Cell Motil 2003, 24:19-249.
27. Betsholtz C, Baumann A, Kenna S, Ashcroft FM, Ashcroft SJ, Berggren PO, et al: Expression of voltage-gated K+ channels in insulin-producing cells. Analysis by polymerase chain reaction. Fabs Lett 1990, 263:121-126.
28. Minami K, Miki T, Kadowaki T, Seino S: Roles of ATP-sensitive K+ channels as metabolic sensors: studies of Kir6.x null mice. Diabetes 2004, 53(Suppl 3):S176-S180.
29. Scraba SG, Sharp GW: Glucose stimulated signaling pathways in biphasic insulin secretion. Diabetes Metab Res Rev 2002, 18:451-463.
30. JI JS, John SA, Ly U, Weiss JN: Mechanosensitivity of the cardiac purinergic potassium channel, A novel channel, configured by Kir3.4 subunits. J Biol Chem 1998, 273:1324-1328.
31. Kubo Y, Adelman JP, Clapham DE, Jan LY, Karschin A, Kurachi Y, et al: International Union of Pharmacology. LIV. Nomenclature and molecular relationships of inwardly rectifying potassium channels. Pharmacol Rev 2005, 57:509-526.
32. Bensimon M, Chang A, Kuroski-de Bold ML, Ponce A, Carreras D, de Bold AJ: Participation of G Proteins in Natriuretic Peptide Hormone Secretion from Heart Atria. Endocrinology 2004, 145:3131-3321.
32. Liu W, Saint DA: Heterogeneous expression of tandem-pore K+ channel genes in adult and embryonic rat heart quantified by real-time polymerase chain reaction. Clin Exp Pharmacol Physiol 2004, 31:174-178.

33. Enyeart JA, Danthi SJ, Enyeart JJ: TREK-1 K+ channels couple angiotensin II receptors to membrane depolarization and aldosterone secretion in bovine adrenal glomerulosa cells. Am J Physiol Endocrinol Metab 2004, 287:E1154-E1165.

34. Terrenoire C, Lauritzen I, Lesage F, Romey G, Lazdunski M: A TREK-1-like potassium channel in atrial cells inhibited by beta-adrenergic stimulation and activated by volatile anesthetics. Circ Res 2001, 89:336-342.

35. Wieland T, Mittmann C: Regulators of G-protein signalling: multifunctional proteins with impact on signalling in the cardiovascular system. Pharmacol Ther 2003, 97:95-115.

36. Doupnik CA, Xu T, Shinaman JM: Profile of RGS expression in single rat atrial myocytes. Biochim Biophys Acta 2001, 1522:97-107.

37. Kardestuncer T, Wu H, Lim AL, Neer EJ: Cardiac myocytes express mRNA for ten RGS proteins: changes in RGS mRNA expression in ventricular myocytes and cultured atria. Faseb J 1998, 438:285-288.

38. Cismowski MJ, Ma C, Ribas C, Xie X, Spruyt M, Lizano JS, et al.: Activation of heterotrimeric G-protein signaling by a ras-related protein. Implications for signal integration. J Biol Chem 2000, 275:23421-23424.

39. Graham TE, Qiao Z, Dorin RL: Dexamethasone inhibits adenylyl cyclase. Biochim Biophys Res Commun 2004, 316:307-312.

40. Graham TE, Prossnitz ER, Dorin RL: Dexamethasone inhibits signal transduction from the Gi-coupled formyl peptide receptor to Erk-1/2 MAP kinases. J Biol Chem 2002, 277:10876-10882.

41. Takeshima H, Nowak MV, Cismowski M, Duzic E, Lanier SM: Activator of G-protein signaling 1 blocks GIRK channel activation by a G-protein-coupled receptor: apparent disruption of receptor signaling complexes. J Biol Chem 2002, 277:13827-13830.

42. Graham TE, Key TA, Kilpatrick K, Dorin RL: Dexamethasone inhibits adenylyl cyclase and a steroid hormone-induced guanosine triphosphate-binding protein, inhibits 3’,5’-cyclic adenosine monophosphate-stimulated secretion in AtT-20 corticotroph cells. Endocrinology 2001, 142:2631-2640.

43. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31:15.

44. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al.: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Bioinformatics 2003, 19:249-264.